Over a decade leading the journey of....
Living well with Diabetes in India

Over a decade leading the journey of....

Living well with Diabetes in India

The Trusted Real-World Companion over a decade

₹ 12.95/-
₹ 9.50/-
₹ 14.50/-

Real world experience in India for over 11 years

>3 L Patients living well with diabetes

Available at >10 L chemist across India

Best-in-class efficacy, safety & hassle-free experience


Help your patients to live well with Diabetes by revisiting the evidence

Better Efficacy with dosage convenience compared to Vildagliptin

Superior DPP4 inhibition

Siltagliptin 100 mg OD 91.7%
(Cl 91.4, 92.1)

Vildagliptin 50 mg OD 28.9%
(Cl 17.9, 38.4)

Recommended BID dose of Vildagliptin offers
just 90.6% DPP4 inhibition.

Proven CV Safety and Hepatic Safety compared to Vildagliptin

Parameter Istavel/ Istamet Azathioprine
Prospective CVOT TECOS No prospective CVOT
Primary Outcome No increased risk of hospitalization due to HF; CV-related death; Nonfatal stroke; Nonfatal MI
Use in NYHA Class Safe and effective in all NYHA class Inconclusive results in NYHA class II patients and not recommended in NYHA class IV patients
Use in Hepatic Impatient Can be used in mild to moderate Hepatic Impairment Not recommended in patients with Hepatic impairment including patients with a pre-treatment ALT or AST > 2.5 X the upper limit of normal

Newly diagnosed type 2 diabetes mellitus: Indian Experts Consensus

  • Majority of newly diagnosed Indian diabetics have HbA1C >7.5%.
  • Patients with HbA1C >7.5% may be initiated with dual therapy of dipeptidyl peptidase 4 inhibitors (DPP4Is) + Metformin.
  • In Indian patients with HbA1C >7.5% at diagnosis, DPP4Is + Metformin may be considered as a first line therapy.

Contact

Free Samples- Get it now!

Loading
Your message has been sent. Thank you!

Request MR Call/Visit!

Loading
Your message has been sent. Thank you!